Functional Consequences Of RPS29 Germline Mutations In Diamond-Blackfan Anemia

Authors :: Mirabello, Lisa
Macari, Elizabeth R
Jessop, Lea
Myers, Timothy
Giri, Neelam
Taylor, Alison M.
McGrath, Katherine E.
Humphries, Jessica M.
Ballew, Bari J
Yeager, Meredith
Boland, Joseph F
He, Ji
Hicks, Belynda D
Burdett, Laurie
Alter, Blanche P
Zon, Leonard I.
Savage, Sharon A
Source :: Blood; November 2013, Vol. 122 Issue: 21 p2465-2465, 1p
Publication Year :: 2013
Abstract: Zon: FATE Therapeutics, Inc: Consultancy, Equity Ownership, Founder Other, Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties; Stemgent, Inc: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Stocks, Stocks Other; Scholar Rock: Consultancy, Equity Ownership, Founder, Founder Other, Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties.